Cell Reports Medicine (Sep 2024)

Clinical-transcriptional prioritization of the circulating proteome in human heart failure

  • Andrew S. Perry,
  • Kaushik Amancherla,
  • Xiaoning Huang,
  • Michelle L. Lance,
  • Eric Farber-Eger,
  • Priya Gajjar,
  • Junedh Amrute,
  • Lindsey Stolze,
  • Shilin Zhao,
  • Quanhu Sheng,
  • Cassandra M. Joynes,
  • Zhongsheng Peng,
  • Toshiko Tanaka,
  • Stavros G. Drakos,
  • Kory J. Lavine,
  • Craig Selzman,
  • Joseph R. Visker,
  • Thirupura S. Shankar,
  • Luigi Ferrucci,
  • Saumya Das,
  • Jane Wilcox,
  • Ravi B. Patel,
  • Ravi Kalhan,
  • Sanjiv J. Shah,
  • Keenan A. Walker,
  • Quinn Wells,
  • Nathan Tucker,
  • Matthew Nayor,
  • Ravi V. Shah,
  • Sadiya S. Khan

Journal volume & issue
Vol. 5, no. 9
p. 101704

Abstract

Read online

Summary: Given expanding studies in epidemiology and disease-oriented human studies offering hundreds of associations between the human “ome” and disease, prioritizing molecules relevant to disease mechanisms among this growing breadth is important. Here, we link the circulating proteome to human heart failure (HF) propensity (via echocardiographic phenotyping and clinical outcomes) across the lifespan, demonstrating key pathways of fibrosis, inflammation, metabolism, and hypertrophy. We observe a broad array of genes encoding proteins linked to HF phenotypes and outcomes in clinical populations dynamically expressed at a transcriptional level in human myocardium during HF and cardiac recovery (several in a cell-specific fashion). Many identified targets do not have wide precedent in large-scale genomic discovery or human studies, highlighting the complementary roles for proteomic and tissue transcriptomic discovery to focus epidemiological targets to those relevant in human myocardium for further interrogation.

Keywords